Novo Nordisk Pharmaceuticals has notified the Therapeutic Goods Administration (TGA) that the limited availability of the glucagon product GlucaGen HypoKit will be extended by one month to 31 October 2023.
For more information on this shortage, including advice for patients and healthcare professionals on accessing and conserving supply, see our medicine shortage alert published on 4 August 2023.
Please note that while the current shortage is expected to end by 31 October 2023, this date may change and we encourage you to check the medicine shortage reports database for updates about the supply of GlucaGen HypoKit.
The Department of Health and Aged Care acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.